Congenital hepatic hemangiomas: Clinical, histologic, and genetic correlation
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Feb 2020 · 1 min read
In brief
In brief
Retrospective study of 16 congenital hepatic hemangioma patients identifies two histologic subtypes associated with GNAQ and PIK3CA mutations. Management ranged from observation to surgical resection, with genetic testing helping confirm diagnosis and potentially guide treatment decisions.
Written by the GCMD Library team from the article.
Background
The guide for monitoring and treatment of congenital hepatic hemangiomas (CHH) will depend on the subtype and the postnatal clinical behavior. Our aim is to present a series of CHH and characterize its clinical, histologic and genetic correlation, compared to cutaneous congenital hemangiomas (CCH).
Material and methods
A retrospective review of CHH patients diagnosed between 1991 and 2018 was performed. Clinical, morphological and histological data were analyzed and deep high-throughput sequencing was performed.
Main results
Sixteen patients with CHH were included. Five patients were followed up with serial ultrasounds while pharmacological treatment (corticosteroids and propranolol) was decided in five. Surgical resection was performed in five owing to hemorrhage and suspicion of malignancy, and the last patient underwent embolization. Histologic analysis was available in 7 patients and confirmed CHH, showing two different histological patterns that could be associated with the presence of somatic pathogenic variants in GNAQ and/or PIK3CA detected in the genetic testing. Review of 7 samples of CCH revealed some histologic differences compared to CHH.
Conclusion
CHH resemble its cutaneous homonym with similar clinical behavior. Histologic analysis can differentiate two subgroups while genetic testing can confirm mutations in GNAQ and in PIK3CA in a subset of CHH.
Type of study
Treatment study.
Level of evidence
IV